JP2009532453A5 - - Google Patents

Download PDF

Info

Publication number
JP2009532453A5
JP2009532453A5 JP2009503668A JP2009503668A JP2009532453A5 JP 2009532453 A5 JP2009532453 A5 JP 2009532453A5 JP 2009503668 A JP2009503668 A JP 2009503668A JP 2009503668 A JP2009503668 A JP 2009503668A JP 2009532453 A5 JP2009532453 A5 JP 2009532453A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound according
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532453A (ja
Filing date
Publication date
Priority claimed from GB0606913A external-priority patent/GB0606913D0/en
Priority claimed from GB0700112A external-priority patent/GB0700112D0/en
Application filed filed Critical
Priority claimed from PCT/GB2007/050183 external-priority patent/WO2007116229A1/en
Publication of JP2009532453A publication Critical patent/JP2009532453A/ja
Publication of JP2009532453A5 publication Critical patent/JP2009532453A5/ja
Pending legal-status Critical Current

Links

JP2009503668A 2006-04-06 2007-04-05 ヘテロサイクリックgpcrアゴニスト Pending JP2009532453A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0606913A GB0606913D0 (en) 2006-04-06 2006-04-06 Compounds
GB0700112A GB0700112D0 (en) 2007-01-04 2007-01-04 Compounds
PCT/GB2007/050183 WO2007116229A1 (en) 2006-04-06 2007-04-05 Heterocyclic gpcr agonists

Publications (2)

Publication Number Publication Date
JP2009532453A JP2009532453A (ja) 2009-09-10
JP2009532453A5 true JP2009532453A5 (enExample) 2010-05-20

Family

ID=38227799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503668A Pending JP2009532453A (ja) 2006-04-06 2007-04-05 ヘテロサイクリックgpcrアゴニスト

Country Status (12)

Country Link
US (1) US20090221639A1 (enExample)
EP (1) EP2013201B1 (enExample)
JP (1) JP2009532453A (enExample)
KR (1) KR20080109075A (enExample)
AU (1) AU2007235673A1 (enExample)
BR (1) BRPI0710839A2 (enExample)
CA (1) CA2646676A1 (enExample)
MX (1) MX2008012814A (enExample)
NO (1) NO20084307L (enExample)
NZ (1) NZ571869A (enExample)
WO (1) WO2007116229A1 (enExample)
ZA (1) ZA200809289B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514828A (ja) * 2007-01-04 2010-05-06 プロシディオン・リミテッド ピペリジンgpcrアゴニスト
BRPI0806312A2 (pt) * 2007-01-04 2011-09-06 Prosidion Ltd agonistas cgpr piperidina
GB0700125D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
CL2008000017A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
CL2008000018A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700122D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2200609A1 (en) * 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
MX2010003117A (es) 2007-09-20 2010-04-01 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
JP2011520969A (ja) * 2008-05-19 2011-07-21 シェーリング コーポレイション 二環式ヘテロ環誘導体およびgpr119モジュレーターとしてのその使用
WO2010084512A1 (en) 2008-12-24 2010-07-29 Cadila Healthcare Limited Novel oxime derivatives
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
KR20120051668A (ko) * 2009-08-05 2012-05-22 다이이찌 산쿄 가부시키가이샤 술폰 유도체
MY156174A (en) 2009-08-05 2016-01-15 Daiichi Sankyo Co Ltd 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
AU2010313469A1 (en) 2009-10-29 2012-06-07 Merck Sharp & Dohme Corp. Bridged Bicyclic Piperidine Derivatives and methods of use thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
PH12013500671A1 (en) 2010-10-08 2018-04-11 Cadila Healthcare Ltd Novel gpr 119 agonists
PL2628733T3 (pl) 2010-10-14 2015-05-29 Daiichi Sankyo Co Ltd Pochodna acylobenzenu
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
AU2012291150A1 (en) 2011-07-29 2014-02-20 Daiichi Sankyo Company, Limited N-hetero-ring-substituted amide derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013062837A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Piperidine derivatives useful as gpr119 agonists
TWI551590B (zh) 2012-01-18 2016-10-01 第一三共股份有限公司 經取代之苯吖唑衍生物
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014019967A1 (en) 2012-08-02 2014-02-06 Boehringer Ingelheim International Gmbh N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6856094A (en) * 1994-06-01 1995-12-21 Yamanouchi Pharmaceutical Co., Ltd. Oxadiazole derivative and medicinal composition thereof
US6699853B2 (en) * 1997-06-16 2004-03-02 Hoechst Schering Agrevo Gmbh 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides
CZ20022100A3 (cs) * 1999-12-16 2002-09-11 Schering Corporation Substituované imidazolové deriváty a farmaceutický prostředek
ES2770035T3 (es) * 2003-04-11 2020-06-30 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
WO2005061489A1 (en) * 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
NZ564758A (en) * 2005-06-30 2011-03-31 Prosidion Ltd G-protein coupled receptor agonists
EP1907383A1 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists

Similar Documents

Publication Publication Date Title
JP2009532453A5 (enExample)
JP2010514832A5 (enExample)
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
JP2013531029A5 (enExample)
JP2011500658A5 (enExample)
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
JP2008525417A5 (enExample)
JP2011527335A5 (enExample)
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
RU2007139634A (ru) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
MY177250A (en) Novel nicotinamide derivative or salt thereof
UA98966C2 (ru) Производные бензазепина, пригодные для использования в качестве антагонистов вазопрессина
RU2013144215A (ru) Средство для борьбы с эндопаразитами
MXPA05008600A (es) Compuestos para el tratamiento de desordenes metabolicos.
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
ATE487474T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
ATE526018T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
RU2013141559A (ru) Способ ингибирования клеток опухоли гамартомы
RU2009125439A (ru) Комбинация ингибитора гда и антиметаболита
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
RU2010115337A (ru) Трициклические гетероциклические производные
PE20120732A1 (es) Agonistas del receptor de esfingosina-1-fosfato
DE602004024382D1 (de) Verbindungen zur behandlung von stoffwechselstörungen